39ORibociclib (RIB) + non-steroidal aromatase inhibitor (NSAI) + goserelin in premenopausal Asian women with hormone-receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC): Results from the randomized phase III MONALEESA-7 study. (25th November 2018) - Im, S-A; Sohn, J; Tripathy, D; Chow, L; Lee, K S; Jung, K H; Babu, G; Im, Y-H; El Saghir, N; Liu, M-C; Diaz-Padilla, I; Alam, J; et al.